Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare fax automation AI extracting referral and authorization data into EHR workflows; eliminating manual fax processing for medical practices where 80% of communications are still faxed.
Tennr is an AI-powered healthcare operations platform that automates fax-based administrative workflows for healthcare providers — extracting data from incoming faxes (referrals, prior authorizations, lab results, patient records) and automatically routing, categorizing, and populating EHR workflows to eliminate the manual data entry that consumes significant administrative staff time at medical practices and health systems. Founded in 2021 and headquartered in New York, Tennr has raised approximately $18 million targeting the persistent problem of healthcare fax volume, as US healthcare still transmits approximately 80% of inter-provider communications via fax.\n\nTennr's AI system reads incoming fax documents, identifies the document type (referral, authorization request, clinical note), extracts key clinical data (patient name, DOB, diagnosis codes, requested procedures), and automatically creates the corresponding workflows in the practice management or EHR system — eliminating the need for front desk staff to manually read faxes, type data into multiple systems, and track follow-up actions. The platform integrates with major EHR systems (Epic, Athenahealth, eClinicalWorks) to push extracted data directly into the right fields.\n\nIn 2025, Tennr operates in the healthcare administrative AI market alongside Thoughtful AI (healthcare billing automation), Olive AI (now restructured), and general RPA platforms that healthcare organizations adapt for administrative workflows. The healthcare fax automation market is significant — large specialty practices can receive thousands of faxes daily, with each requiring manual processing. Tennr's AI-native approach for healthcare document understanding (trained specifically on medical fax content) differentiates it from generic document AI. The 2025 strategy focuses on expanding to more specialty practices, deepening integrations with more EHR platforms, and adding prior authorization automation as a high-value workflow.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.